Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae

Nan Yao Lee; Wei Han Huang; Ko Chung Tsui; Po Ren Hsueh; Wen Chien Ko

doi:10.1016/j.diagmicrobio.2010.12.008

Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae

Nan Yao Lee, Wei Han Huang, Ko Chung Tsui, Po Ren Hsueh, Wen Chien Ko

內科學科

研究成果: Article › 同行評審

25 引文斯高帕斯（Scopus）

摘要

For 244 patients with bacteremia due to extended-spectrum β-lactamase (ESBL)-producing Escherichia coli or Klebsiella pneumoniae treated by ertapenem (73, 29.9%) or either imipenem or meropenem (171, 70.1%), the therapeutic efficacy was evaluated. Ertapenem therapy was effective for patients with ESBL-producing E. coli or K. pneumoniae bacteremia in terms of mortality and microbiological responses, as compared with imipenem or meropenem.

原文	English
頁（從 - 到）	150-153
頁數	4
期刊	Diagnostic Microbiology and Infectious Disease
卷	70
發行號	1
DOIs	https://doi.org/10.1016/j.diagmicrobio.2010.12.008
出版狀態	Published - 2011 5月

All Science Journal Classification (ASJC) codes

微生物學（醫學）
傳染性疾病

存取文件

10.1016/j.diagmicrobio.2010.12.008

其它文件與鏈接

引用此

@article{2dd77a39a05940e7ad62f50faa147c3c,

title = "Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae",

abstract = "For 244 patients with bacteremia due to extended-spectrum β-lactamase (ESBL)-producing Escherichia coli or Klebsiella pneumoniae treated by ertapenem (73, 29.9%) or either imipenem or meropenem (171, 70.1%), the therapeutic efficacy was evaluated. Ertapenem therapy was effective for patients with ESBL-producing E. coli or K. pneumoniae bacteremia in terms of mortality and microbiological responses, as compared with imipenem or meropenem.",

author = "Lee, {Nan Yao} and Huang, {Wei Han} and Tsui, {Ko Chung} and Hsueh, {Po Ren} and Ko, {Wen Chien}",

year = "2011",

month = may,

doi = "10.1016/j.diagmicrobio.2010.12.008",

language = "English",

volume = "70",

pages = "150--153",

journal = "Diagnostic Microbiology and Infectious Disease",

issn = "0732-8893",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae

AU - Lee, Nan Yao

AU - Huang, Wei Han

AU - Tsui, Ko Chung

AU - Hsueh, Po Ren

AU - Ko, Wen Chien

PY - 2011/5

Y1 - 2011/5

N2 - For 244 patients with bacteremia due to extended-spectrum β-lactamase (ESBL)-producing Escherichia coli or Klebsiella pneumoniae treated by ertapenem (73, 29.9%) or either imipenem or meropenem (171, 70.1%), the therapeutic efficacy was evaluated. Ertapenem therapy was effective for patients with ESBL-producing E. coli or K. pneumoniae bacteremia in terms of mortality and microbiological responses, as compared with imipenem or meropenem.

AB - For 244 patients with bacteremia due to extended-spectrum β-lactamase (ESBL)-producing Escherichia coli or Klebsiella pneumoniae treated by ertapenem (73, 29.9%) or either imipenem or meropenem (171, 70.1%), the therapeutic efficacy was evaluated. Ertapenem therapy was effective for patients with ESBL-producing E. coli or K. pneumoniae bacteremia in terms of mortality and microbiological responses, as compared with imipenem or meropenem.

UR - http://www.scopus.com/inward/record.url?scp=79955028237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955028237&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2010.12.008

DO - 10.1016/j.diagmicrobio.2010.12.008

M3 - Article

C2 - 21398070

AN - SCOPUS:79955028237

SN - 0732-8893

VL - 70

SP - 150

EP - 153

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

IS - 1

ER -

Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae

摘要

All Science Journal Classification (ASJC) codes

存取文件

其它文件與鏈接

指紋

引用此